Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

half year results on the 28th August, 2008.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in late 2008, and TB-403 (Anti-PlGF), which has begun Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospect
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 GenomeDx ... genomic analysis platform, successfully classified various subtypes ... expression of certain biomarkers, including one type ... this unique genomic signature has potential as ... neoadjuvant chemotherapy in patients with muscle-invasive bladder ...
(Date:6/1/2015)... June 1, 2015  The Val Skinner Foundation is ... science curriculum for high school students focused on cancer ... annual LIFE Event (LPGA Pros in the Fight ... Club in West Caldwell, N.J. ... stars raised more than $500,000 on Monday, bringing the ...
(Date:6/1/2015)... Mich. , June 1, 2015  Neogen Corporation (NASDAQ: ... assets of Sterling Test House, a leading commercial food testing ... that the acquired laboratory will serve as a base for ... Sterling Test House was incorporated ... all of the food safety and water quality testing for ...
(Date:6/1/2015)... , June 1, 2015   Epic Sciences, Inc. ... products and offerings to personalize and advance the treatment ... expanded the available credit under its existing credit facility ... agreement increases the available capacity of the facility from ... maturity by 27 months to April 1, 2019.  The ...
Breaking Biology Technology:GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Val Skinner Foundation Announces Partnership With Discovery Education 2Neogen acquires India food safety company 2Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... Sept. 1 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus,Biotech Inc. ... manufacturer and marketer of a variety of cactus-based ... successfully completed the trial,production of cactus-based cigarettes and ... in 2009: (i) low nicotine and (ii) zero ...
... ANNAPOLIS, Md., Sept. 1 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, announced today that management will ... 2009. The Company is scheduled to present on Thursday, ... Salon (5th Floor) at the New York Palace Hotel, New ...
... FORT LAUDERDALE, Fla., Sept. 1 OmniComm Systems, Inc. (OTC ... data capture (EDC) solutions for clinical trials, and ... announced today that three additional clinical research organizations ... the CRO Preferred Program. The partnership allows CROs in the ...
Cached Biology Technology:China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 2China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 3OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 3
(Date:5/28/2015)... Va. , May 28, 2015 ... release of a new report titled "Markets for ... (reversible polymers, inorganic capsule and vascular systems, biomaterials, ... will grow to around $2.7 billion by 2020. ... from n-tech,s extensive coverage of smart materials. Other recent ...
(Date:5/25/2015)... 2015  Australia,s market for wearable technologies is considered ... the advent of several trials and prototypes. The release ... expected to ignite interest in wearables as well as ... . This in turn will spur greater innovation ... partnerships amongst vendors and distributors. Photo ...
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4
... STANFORD, Calif. - Life is almost unbearably complex. Humans ... off in dizzying combinations and sequences during their relentless ... understand the machinations of the proteins behind the genomic ... disposal, courtesy of researchers at the Stanford University School ...
... nearly 1.5 million Americans have been diagnosed with autism spectrum ... to have some form of autism, according to the latest ... (CDC). Find out what new research and treatment plans are ... over the past few decades at a panel discussion at ...
... Docosahexaenoic acid (DHA), an omega-3 fatty acid, is essential ... premature infants may be deficient in DHA because they ... the fatty acid accumulates in tissues. In addition, their ... the risk of malnutrition. Furthermore, breastfeeding mothers, ...
Cached Biology News:New Stanford tool enables wider analyses of genome 'deep sequencing' 2New Stanford tool enables wider analyses of genome 'deep sequencing' 3Expert panel to discuss autism spectrum disorders 2Giving DHA supplements to breastfeeding mothers 2
... ( Abpromise for all tested ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to KLH, ... Human Decorin (fragment 36-49 of the ... Entrez GeneID: 1634 ...
GLP expression profiling service on the Affymetrix platform. Starting material can be blood, tissue or RNA. 5 day turnaround. Standard and custom post analyses of microarray data available....
... a fluorescent microscopy-based imaging system that accurately ... automatically calculates cell viability, in a single ... the variability associated with the subjective interpretation ... the EasyCount ViaSure Kit, up to six ...
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
Biology Products: